Dupilumab
- Generic Name
- Dupilumab
- Brand Names
- Dupixent
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1190264-60-8
- Unique Ingredient Identifier
- 420K487FSG
- Background
Dupilumab is a fully human monoclonal antibody of the immunoglobulin G4 subclass that binds to the interleukin-4 (IL-4) receptor, inhibiting the receptor signaling pathways. As an interleukin-4 receptor alpha antagonist, dupilumab inhibits the signaling of pro-inflammatory cytokines, called interleukins (IL), that induce inflammatory and immunological reacti...
- Indication
In the US, dupilumab is indicated for the treatment of patients aged six months and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. In Europe and Canada, the drug for this indication is approved for patients aged six years and older. In E...
- Associated Conditions
- Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP), Eosinophilic Esophagitis, Moderate to Severe Asthma, Moderate to Severe Atopic Dermatitis, Oral Steroid-Dependent Asthma (Disorder), Prurigo Nodularis, Severe Asthma, Severe Atopic Dermatitis, Moderate Atopic dermatitis, Moderate Prurigo Nodularis, Severe Prurigo Nodularis
- Associated Therapies
- Add-on therapy, Maintenance therapy
Dupilumab in Severe Chronic Hand Eczema
- First Posted Date
- 2020-08-13
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 30
- Registration Number
- NCT04512339
- Locations
- 🇳🇱
University Medical Center Groningen, Groningen, Netherlands
Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)
- Conditions
- Interventions
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 62
- Registration Number
- NCT04442269
- Locations
- 🇬🇧
Regeneron Study Site, Bradford, West Yorkshire, United Kingdom
Effect of Dupilumab on Aspirin Intolerance
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 30
- Registration Number
- NCT04442256
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)
- Conditions
- Interventions
- First Posted Date
- 2020-06-05
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 133
- Registration Number
- NCT04417894
- Locations
- 🇵🇱
Regeneron Study Site, Wroclaw, Poland
The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 109
- Registration Number
- NCT04400318
- Locations
- 🇺🇸
Allianz Research Institute Site Number : 8400020, Westminster, California, United States
🇺🇸The Lung Research Center Site Number : 8400010, Chesterfield, Missouri, United States
🇧🇬Investigational Site Number : 1000004, Montana, Bulgaria
Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
- Conditions
- Interventions
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 102
- Registration Number
- NCT04394351
- Locations
- 🇨🇦
Regeneron Study Site, London, Ontario, Canada
Efficacy of Dupilumab for Patients With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 50
- Registration Number
- NCT04362501
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
Evaluation of Dupilumab in Patients With Atopic Keratoconjunctivitis (AKC)
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Andover Eye Associates
- Target Recruit Count
- 42
- Registration Number
- NCT04296864
- Locations
- 🇺🇸
Mercy Clinic Eye Specialists, Springfield, Missouri, United States
🇺🇸Northwell Health Physician Partners Ophthalmology at Great Neck, Great Neck, New York, United States
🇺🇸Premiere Practice Management, LLC, Los Angeles, California, United States
Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis
- First Posted Date
- 2020-02-27
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT04287608
- Locations
- 🇺🇸
Regeneron Study Site, Houston, Texas, United States
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
- Conditions
- Interventions
- First Posted Date
- 2019-12-20
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 98
- Registration Number
- NCT04206553
- Locations
- 🇨🇳
Regeneron study Site, Taoyuan City, Taiwan
🇩🇪Regeneron Study Site 2, Dresden, Saxony, Germany
🇵🇱Regeneron Study site', Wroclaw, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.